Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Heider

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Artificial Life|August 23, 2023
Assessing Model Requirements for Explainable AI: A Template and Exemplary Case StudyMichael Heider, Helena Stegherr, Richard Nordsieck, et al.
Oncology Research and Treatment|November 8, 2021
Multiple Myeloma: Molecular Pathogenesis and Disease EvolutionMichael Heider, Katharina Nickel, Marion Högner, et al.
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|June 27, 2021
Cyclophosphamide plus etoposide is a safe and effective mobilization regimen in patients with multiple myelomaMichael Heider, Sandra Grass, Veronika Dill, et al.
Nature|January 31, 2024
Stress response silencing by an E3 ligase mutated in neurodegenerationDiane L Haakonsen, Michael Heider, Andrew J Ingersoll, et al.
EJNMMI Research|January 31, 2022
Initial evaluation of [<sup>18</sup>F]-FACBC for PET imaging of multiple myelomaVolker Morath, Michael Heider, Markus Mittelhäuser, et al.
Nature|May 6, 2025
Molecular basis of SIFI activity in the integrated stress responseZhi Yang, Diane L Haakonsen, Michael Heider, et al.
British Journal of Haematology|May 1, 2020
Prognostic value of indoleamine 2,3 dioxygenase in patients with higher-risk myelodysplastic syndromes treated with azacytidineCatharina Müller-Thomas, Michael Heider, Guido Piontek, et al.
Biorxiv : the Preprint Server for Biology|May 18, 2026
Localized heme sensing through a ternary molecular glueMichael Heider, Clara Hipp, Zhi Yang, et al.
Blood Advances|November 12, 2021
MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myelomaJacob Stroh, Anja Seckinger, Michael Heider, et al.
The EMBO Journal|September 5, 2022
The OTUD6B-LIN28B-MYC axis determines the proliferative state in multiple myelomaCarmen Paulmann, Ria Spallek, Oleksandra Karpiuk, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Artificial Life|August 23, 2023
Assessing Model Requirements for Explainable AI: A Template and Exemplary Case StudyMichael Heider, Helena Stegherr, Richard Nordsieck, et al.
Oncology Research and Treatment|November 8, 2021
Multiple Myeloma: Molecular Pathogenesis and Disease EvolutionMichael Heider, Katharina Nickel, Marion Högner, et al.
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|June 27, 2021
Cyclophosphamide plus etoposide is a safe and effective mobilization regimen in patients with multiple myelomaMichael Heider, Sandra Grass, Veronika Dill, et al.
Nature|January 31, 2024
Stress response silencing by an E3 ligase mutated in neurodegenerationDiane L Haakonsen, Michael Heider, Andrew J Ingersoll, et al.
EJNMMI Research|January 31, 2022
Initial evaluation of [<sup>18</sup>F]-FACBC for PET imaging of multiple myelomaVolker Morath, Michael Heider, Markus Mittelhäuser, et al.
Nature|May 6, 2025
Molecular basis of SIFI activity in the integrated stress responseZhi Yang, Diane L Haakonsen, Michael Heider, et al.
British Journal of Haematology|May 1, 2020
Prognostic value of indoleamine 2,3 dioxygenase in patients with higher-risk myelodysplastic syndromes treated with azacytidineCatharina Müller-Thomas, Michael Heider, Guido Piontek, et al.
Biorxiv : the Preprint Server for Biology|May 18, 2026
Localized heme sensing through a ternary molecular glueMichael Heider, Clara Hipp, Zhi Yang, et al.
Blood Advances|November 12, 2021
MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myelomaJacob Stroh, Anja Seckinger, Michael Heider, et al.
The EMBO Journal|September 5, 2022
The OTUD6B-LIN28B-MYC axis determines the proliferative state in multiple myelomaCarmen Paulmann, Ria Spallek, Oleksandra Karpiuk, et al.
Pageof 2